Tharimmune, Inc. | Finanzwire

BRIEF

published on 10/25/2024 at 14:05, 28 days 19 hours ago

Tharimmune to Present Key Findings at Upcoming Conferences

Biotechnology Conference Therapeutics Tharimmune Immunology
PRESS RELEASE

published on 10/25/2024 at 14:00, 28 days 19 hours ago

Tharimmune Announces Upcoming Conference Presentations
Tharimmune, Inc. to present new results from Phase 1 trial of TH104 at ACG 2024 Annual Scientific Meeting. CEO to speak at 2024 ThinkEquity Conference in NY. Webcast available

Tharimmune Inc. Phase 1 Trial Clinical-stage Biotechnology ACG 2024 ThinkEquity Conference
BRIEF

published on 07/22/2024 at 14:35, 4 months ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Scientific Advisory Board TH104 Tharimmune David Jones Autoimmune Liver Disease
PRESS RELEASE

published on 07/22/2024 at 14:30, 4 months ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune, Inc. appoints Prof. David Jones, an expert in autoimmune liver disease, to its Scientific Advisory Board. Prof. Jones brings valuable insights to advance lead drug candidate TH104 for PBC patients

Scientific Advisory Board TH104 Tharimmune David Jones Autoimmune Liver Disease
BRIEF

published on 07/17/2024 at 14:35, 4 months 5 days ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Biotechnology Strategic Advisor Tharimmune David H. Clarke
PRESS RELEASE

published on 07/17/2024 at 14:30, 4 months 5 days ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Tharimmune, Inc. appoints David H. Clarke as Strategic Advisor, bringing valuable experience to enhance company's leadership and growth in inflammation and immunology therapeutics

Biotechnology Appointment Tharimmune Inc. Inflammation David H. Clarke
BRIEF

published on 07/10/2024 at 14:35, 4 months 12 days ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Biotechnology Strategic Advisor Tharimmune Jules Haimovitz Phase 2 Program
PRESS RELEASE

published on 07/10/2024 at 14:30, 4 months 12 days ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Tharimmune, Inc. appoints Jules Haimovitz as Strategic Advisor, leveraging his biotechnology leadership and experience. The move enhances Tharimmune's clinical programs and FDA Phase 2 progress

Biotechnology Tharimmune Inc. Clinical Programs Jules Haimovitz FDA Phase 2
BRIEF

published on 06/17/2024 at 14:05, 5 months 5 days ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104

FDA TH104 Phase 2 Trial Tharimmune PBC
PRESS RELEASE

published on 06/17/2024 at 14:00, 5 months 5 days ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive FDA Type C meeting feedback for TH104 Phase 2 program, targeting pruritus in PBC patients, plans 505(b)(2) pathway for approval

FDA Feedback Tharimmune Inc TH104 Phase 2 Pruritus PBC Patients

Published on 11/22/2024 at 23:55, 9 hours 25 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 50 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 15 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 15 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 50 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 15 hours 6 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 20 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 27 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 25 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 20 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 45 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 14 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News